| ANOTHER-LARGE-DISTRIBUTOR |
ANOTHER-LARGE-DISTRIBUTOR |
90%
|
Company sold products and services totaling approximately $ 106,000 ( 11.3 % ) to another large distributor |
| ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB |
ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB |
90%
|
Company sold products and services totaling approximately $ 169,000 ( 11.7 % ) to another large medical practice group and distributor |
| INDIVIDUAL-MEDICAL-PRACTICE |
INDIVIDUAL-MEDICAL-PRACTICE |
90%
|
During the year ended October 31, 2023, the Company sold products and services totaling approximately $ 460,000 ( 10.1 % ) to an individual medical practice |
| LARGE-DISTRIBUTOR |
LARGE-DISTRIBUTOR |
90%
|
Company sold products and services totaling approximately $ 108,000 ( 11.5 % ) to a large distributor |
| LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR |
LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR |
90%
|
Company sold products and services totaling approximately $ 237,000 ( 16.4 % ) to a large medical practice group and distributor |
| EXOTROPIN |
EXOTROPIN |
80%
|
Company is entitled to receive commissions on the net sales value of Exotropin products sold to pre-approved customers introduced by the Company |
| BESPOKE-TRICYCLES-INC |
BESPOKE-TRICYCLES-INC |
62%
|
nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |
| EXOTROPIN-LLC |
EXOTROPIN-LLC |
62%
|
nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |
| FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC |
FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC |
62%
|
0 Fair value of vested options issued - - 953,000 - 953,000 Fair value of vested warrants issued - - 2,450,000 - 2,450,000 Net loss - - - ( 4,705,000 ) ( 4,705,000 ) Balance October 31, 2024 6,344,81… |
| ORGANICELL-REGENERATIVE-MEDICINE-INC |
ORGANICELL-REGENERATIVE-MEDICINE-INC |
62%
|
nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |